Cofactor Genomics Acquires Narus Biotechnologies
News Feb 04, 2016
This acquisition advances Cofactor’s expansion into RNA-based diagnostics and further solidifies their plans for the development and delivery of RNA-based tests for cancer and neurodegenerative disease. Cofactor’s initial products are aimed at the pre-clinical and clinical segments of the pharmaceutical market, where Cofactor has nine of the world’s largest pharmaceutical companies under contract for studies using RNA to understand disease.
“In addition to acquiring Narus’ assets related to RNA biomarkers, we gain an extremely talented team that is already helping to accelerate Cofactor’s RNA-based diagnostic roadmap,” stated Dr. Jarret Glasscock, Cofactor’s CEO. “This acquisition brings two major changes to Cofactor: it establishes Cofactor’s San Francisco presence and secures the resources necessary to change the face of medicine by using RNA to detect disease and monitor treatment progression.”
“There is a multitude of diseases where a tissue biopsy is just not feasible and current techniques like cell-free DNA are noninformative. We’re excited to integrate the techniques we’ve developed using cell-free RNA with the proven track record of an institution like Cofactor,” stated Raman Talwar, Narus co-founder and Cofactor’s newly appointed Director of Diagnostic Development.
Putting Proteins in Their Proper PlaceNews
Everything in the cell has its right place. This includes certain molecules called RNA-binding proteins. When these are misplaced, they can end up causing dangerous clumps that are typical of diseases like ALS. A new study has found a way to send these proteins home.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018
6th International Conference on Neurodegenerative Disorders and Stroke
Oct 22 - Oct 23, 2018
16th Annual Conference on Laboratory Medicine and Pathology
Sep 17 - Sep 18, 2018